Health
Immune dysregulation can affect the efficacy of CAR T therapy in some lymphoma patients – News-Medical.Net
Chimeric antigen receptor T-cell therapy, or CAR T, has been a breakthrough in the treatment of blood cancers such as acute lymphoblastic leukemia and diffuse large…
Chimeric antigen receptor T-cell therapy, or CAR T, has been a breakthrough in the treatment of blood cancers such as acute lymphoblastic leukemia and diffuse large B-cell lymphoma. Clinical studies have shown overall response rates of more than 80% with an ongoing response of nearly 40% more than two years after therapy. However, the cellular immunotherapy doesn’t work for every patient.
Moffitt Cancer Center, one of the leading centers for cellular immunotherapy, is researching why some patients…
-
Noosa News17 hours agoA World-Premiere Exhibition Dedicated to Crocodiles Is Snapping Its Way Into Queensland Museum Kurilpa, Then Touring Nationally
-
General24 hours agoTabcorp fined $4 million for spamming customers with thousands of unlawful marketing messages
-
General16 hours agoGippsland exhibition explores Joseph Turner’s impact on Australian landscape art
-
General22 hours agoWhatsApp to start showing ads to its users